ST segment resolution as a tool for assessing the efficacy of reperfusion therapy
JA de Lemos, E Braunwald - Journal of the American College of …, 2001 - jacc.org
Rapid, simple and inexpensive measures are needed to assess the efficacy of reperfusion
therapy both in clinical practice and in clinical trials testing novel reperfusion regimens. In …
therapy both in clinical practice and in clinical trials testing novel reperfusion regimens. In …
Percutaneous coronary intervention and adjunctive pharmacotherapy in women: a statement for healthcare professionals from the American Heart Association
More than 1.2 million percutaneous coronary interventions are performed annually in the
United States, with only an estimated 33% performed in women, despite the established …
United States, with only an estimated 33% performed in women, despite the established …
Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 …
HC Herrmann, DJ Moliterno, EM Ohman… - Journal of the American …, 2000 - jacc.org
OBJECTIVES We examined the utility of early percutaneous coronary intervention (PCI) in a
trial that encouraged its use after thrombolysis and glycoprotein IIb/IIIa inhibition for acute …
trial that encouraged its use after thrombolysis and glycoprotein IIb/IIIa inhibition for acute …
Review of immediate angioplasty after fibrinolytic therapy for acute myocardial infarction: insights from the RESCUE I, RESCUE II, and other contemporary clinical …
SG Ellis, ER da Silva, CM Spaulding, M Nobuyoshi… - American heart …, 2000 - Elsevier
Background Prompt restoration of Thrombolysis In Myocardial Infarction (TIMI) grade 3 flow
improves survival in patients with acute ST-segment elevation myocardial infarction (MI) …
improves survival in patients with acute ST-segment elevation myocardial infarction (MI) …
Left ventricular remodeling after primary coronary angioplasty in patients treated with abciximab or intracoronary adenosine
AS Petronio, M De Carlo, N Ciabatti, G Amoroso… - American heart …, 2005 - Elsevier
BACKGROUND: Primary angioplasty is the best treatment of acute myocardial infarction but
fails to achieve adequate myocardial reperfusion in 25% to 30% of patients, despite TIMI …
fails to achieve adequate myocardial reperfusion in 25% to 30% of patients, despite TIMI …
Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non‐ST segment elevation acute coronary …
X Bosch, J Marrugat, J Sanchis - Cochrane Database of …, 2013 - cochranelibrary.com
Background During percutaneous coronary intervention (PCI), and in non‐ST segment
elevation acute coronary syndromes (NSTEACS), the risk of acute vessel occlusion by …
elevation acute coronary syndromes (NSTEACS), the risk of acute vessel occlusion by …
Arterial status after intravenous TPA therapy for ischaemic storke. A need for further interventions
I Christou, WS Burgin, AV Alexandrov… - International …, 2001 - search.proquest.com
BACKGROUND: Intravenous tissue plasminogen activator (TPA) is an approved therapy for
acute ischaemic stroke in the United States. We aimed to noninvasively monitor the therapy …
acute ischaemic stroke in the United States. We aimed to noninvasively monitor the therapy …
Reteplase: a review of its use in the management of thrombotic occlusive disorders
D Simpson, MAA Siddiqui, LJ Scott… - American journal of …, 2006 - Springer
Reteplase (Retavase®) is a plasminogen activator, mimicking endogenous tissue
plasminogen activator (t-PA), a serine protease, converting plasminogen to plasmin and …
plasminogen activator (t-PA), a serine protease, converting plasminogen to plasmin and …
Peripheral artery occlusion: treatment with abciximab plus urokinase versus with urokinase alone—a randomized pilot trial (the PROMPT study)
SH Duda, G Tepe, O Luz, K Ouriel, K Dietz, U Hahn… - Radiology, 2001 - pubs.rsna.org
PURPOSE: To evaluate the combination of a platelet glycoprotein IIb/IIIa complex receptor
inhibitor and urokinase for treatment of recent (≤ 6 weeks) arterial occlusion of the legs …
inhibitor and urokinase for treatment of recent (≤ 6 weeks) arterial occlusion of the legs …
Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation
T Ibbotson, JK McGavin, KL Goa - Drugs, 2003 - Springer
Abciximab | Drugs Skip to main content SpringerLink Account Menu Find a journal Publish with
us Track your research Search Cart 1.Home 2.Drugs 3.Article Abciximab An Updated Review …
us Track your research Search Cart 1.Home 2.Drugs 3.Article Abciximab An Updated Review …